本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 （二）影响经营业绩的主要因素 1、2025年，公司实现营业收入34,959.86万元，较上年同期增长8.59%，其中PEEK材料神经外科产品实 现收入22,568.54万元，较上年同期增长10.36%。 2、报告期归属于母公司所有者的净利润9,881.74万元，较上年同期增长11.79%，与公司收入增速趋 同。 三、风险提示 （一）公司不存在影响本次业绩快报内容准确性的重大不确定因素。 （二）本公告所载数据仅为初步核算数据，具体准确的财务数据以公司正式披露的经审计后的2025年年 报为准，敬请广大投资者注意投资风险。 2.以上财务数据及指标以合并报表数据填制，但未经审计，最终结果以公司2025年年度报告为准。数据 若有尾差，为四舍五入所致。 ...

格隆汇2月27日丨康拓医疗(688314.SH)公布2025年度业绩快报，2025年，公司实现营业收入3.50亿元， 较上年同期增长8.59%；实现归属于母公司所有者净利润9881.74万元，较上年同期增长11.79%；归属于 母公司所有者的扣除非经常性损益的净利润9186.22万元，较上年同期增长22.71%。2025年，公司财务 状况良好，报告期末总资产9.10亿元，较报告期初增长21.78%；归属于母公司的所有者权益7.18亿元， 较报告期初增长12.99%；归属于母公司所有者的每股净资产为8.84元/股，较报告期初增长13.04%。 影响经营业绩的主要因素：1、2025年，公司实现营业收入3.50亿元，较上年同期增长8.59%，其中 PEEK材料神经外科产品实现收入2.26亿元，较上年同期增长10.36%。2、报告期归属于母公司所有者的 净利润9881.74万元，较上年同期增长11.79%，与公司收入增速趋同。 ...

康拓医疗发布业绩快报，2025年度实现营业总收入3.5亿元，同比增长8.59%；净利润9881.74万元，同 比增长11.79%。2025年，公司实现营业收入3.5亿元，较上年同期增长8.59%，其中PEEK材料神经外科 产品实现收入2.26亿元，较上年同期增长10.36%。 ...

截至9月30日，康拓医疗股东户数5879.00，较上期增加15.30%；人均流通股13818股，较上期减少 13.27%。2025年1月-9月，康拓医疗实现营业收入2.51亿元，同比增长4.57%；归母净利润7671.52万元， 同比增长0.00%。 分红方面，康拓医疗A股上市后累计派现1.68亿元。近三年，累计派现1.02亿元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 融资方面，康拓医疗当日融资买入479.48万元。当前融资余额9024.47万元，占流通市值的2.99%，融资 余额超过近一年50%分位水平，处于较高位。 融券方面，康拓医疗1月29日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西安康拓医疗技术股份有限公司位于陕西省西安市高新区毕原一路西段1451号，成立日期 2005年 ...

11月21日，康拓医疗跌4.72%，成交额3175.10万元。两融数据显示，当日康拓医疗获融资买入额419.67 万元，融资偿还668.98万元，融资净买入-249.32万元。截至11月21日，康拓医疗融资融券余额合计1.04 亿元。 融资方面，康拓医疗当日融资买入419.67万元。当前融资余额1.04亿元，占流通市值的4.17%，融资余 额超过近一年80%分位水平，处于高位。 截至9月30日，康拓医疗股东户数5879.00，较上期增加15.30%；人均流通股13818股，较上期减少 13.27%。2025年1月-9月，康拓医疗实现营业收入2.51亿元，同比增长4.57%；归母净利润7671.52万元， 同比增长0.00%。 分红方面，康拓医疗A股上市后累计派现1.68亿元。近三年，累计派现1.02亿元。 责任编辑：小浪快报 融券方面，康拓医疗11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西安康拓医疗技术股份有限公司位于陕西省西安市高新区毕原一路西段1451号，成立日期 200 ...

Core Viewpoint - Kangtuo Medical experienced a decline of 5.62% on September 11, with a stock price of 36.43 yuan per share and a total market capitalization of 2.96 billion yuan [1]. Company Overview - Xi'an Kangtuo Medical Technology Co., Ltd. was established on March 14, 2005, and went public on May 18, 2021. The company specializes in the research, production, and sales of three categories of implantable medical devices [1]. - The revenue composition of the company includes: 63.86% from PEEK material neurosurgical products, 22.54% from titanium material neurosurgical products, 10.97% from other products, and 2.62% from supplementary products [1]. Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with the Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, representing 3.51% of the fund's net value, making it the sixth-largest holding [2]. - The fund has reported a floating loss of approximately 14,400 yuan as of the latest data [2]. Fund Manager Information - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 93 days. The total asset size of the fund is 352 million yuan [3]. - During Li Bingwei's tenure, the best fund return was 61.7%, while the worst return was -11.19% [3].

Company Overview - Kangtuo Medical, established on March 14, 2005, is located in Xi'an, Shaanxi Province, and was listed on May 18, 2021. The company specializes in the research, production, and sales of three types of implantable medical devices [1] - The company's main business revenue composition includes: PEEK material neurosurgical products (63.86%), titanium material neurosurgical products (22.54%), other products (10.97%), and supplementary products (2.62%) [1] Stock Performance - On September 3, Kangtuo Medical's stock rose by 5.04%, reaching a price of 38.16 CNY per share, with a trading volume of 71.24 million CNY and a turnover rate of 2.36%. The total market capitalization is 3.1 billion CNY [1] Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with its Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, accounting for 3.51% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.69%, ranking 1474 out of 8180 in its category, and a cumulative return of 29.01% since its inception [2] Fund Manager Profile - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 85 days. The total asset size of the fund is 352 million CNY, with the best return during his tenure being 62.49% and the worst being -11.19% [3]

Group 1 - The core point of the news is that Kangtuo Medical experienced a decline of 5.15% in its stock price, reaching 37.17 yuan per share, with a total market capitalization of 3.02 billion yuan [1] - Kangtuo Medical, established on March 14, 2005, and listed on May 18, 2021, specializes in the research, production, and sales of three types of implantable medical devices [1] - The revenue composition of Kangtuo Medical includes 63.94% from PEEK material neurosurgical products, 22.42% from titanium material neurosurgical products, 10.47% from other products, and 3.18% from supplementary products [1] Group 2 - According to data, a fund under Jianxin Fund holds a significant position in Kangtuo Medical, with Jianxin Flexible Allocation Mixed A (000270) owning 106,700 shares, representing 1.18% of the fund's net value [2] - The Jianxin Flexible Allocation Mixed A fund has a total scale of 112 million yuan and has achieved a return of 49.44% this year, ranking 464 out of 8190 in its category [2] - The fund has also seen a remarkable return of 99.9% over the past year, ranking 298 out of 7966 in its category, and a cumulative return of 152.36% since its inception [2] Group 3 - The fund manager of Jianxin Flexible Allocation Mixed A is Ye Letian, who has a tenure of 13 years and 164 days, with the fund's total asset scale at 6.53 billion yuan [3] - During Ye Letian's tenure, the best fund return was 241.01%, while the worst was -18.94% [3] - The co-manager, Guo Zhiteng, has a tenure of 1 year and 266 days, managing a fund scale of 625 million yuan, with a best return of 155.31% and a worst return of 12.27% during his tenure [3]

Group 1 - The core viewpoint of the news is that Kangtuo Medical has shown stable trading activity with a slight increase in financing and a notable balance in margin trading as of August 26 [1] - On August 26, Kangtuo Medical's stock price remained unchanged at 0.00%, with a trading volume of 105 million yuan and a financing buy-in amount of 16.49 million yuan, while the financing repayment was 20.12 million yuan, resulting in a net financing outflow of 3.62 million yuan [1] - As of August 26, the total margin trading balance for Kangtuo Medical was 133 million yuan, which accounts for 4.10% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of March 31, the number of shareholders for Kangtuo Medical increased by 10.54% to 4,435, while the average circulating shares per person decreased by 9.54% to 18,317 shares [2] - For the first quarter of 2025, Kangtuo Medical reported a revenue of 82.49 million yuan, representing a year-on-year growth of 17.98%, and a net profit attributable to shareholders of 24.05 million yuan, which is a 20.63% increase year-on-year [2] - Since its A-share listing, Kangtuo Medical has distributed a total of 152 million yuan in dividends, with 85.42 million yuan distributed over the past three years [3]